Sanofi's Lantus (insulin glargine) dramatically changed the insulin antidiabetics landscape and, with an estimated 80% share of the long-acting basal analogs market, the French firm is currently the clear leader in this segment. However, there are several threats to the blockbuster looming, which have prompted Sanofi to raise its game by developing a new suped-up version Lantus – insulin glargine U300. Datamonitor Healthcare's Sebastian Heinzmann explores the chances for this new arrival in an increasingly competitive market.

The safety and efficacy profile of Lilly's dulaglutide must measure up to Novo Nordisk's Victoza if it is to become a contender in the diabetes market, but as Datamonitor Healthcare analyst Dr Sebastian Heinzmann explains, it could do more than just that.